98% of Servier brand-name medicines
active ingredients are synthesized in France.
Over 150 countries
in which the Group’s medicines are distributed
4 therapeutic areas
oncology, cardiometabolism, neuroscience and immuno-inflammation
in clinical development, including 19 new molecular entities (December 2021).
16 chemical and pharmaceutical production sites
15 International Centers for Therapeutic Research
and 6 Research centers (3 in France, 1 in Denmark, 1 in Hungary and 1 in the US).
€4.7 billion euros in revenue in 2020/2021
comprising €3.3 billion for brand-name medicines and €1.4 billion for generic medicines.
More than 20% of revenue from brand-name medicines invested in R&D
34th largest pharmaceutical Group worldwide
and 2nd largest pharmaceutical Group in France.
A leader position in cardiology in France
4th leading pharmaceutical Group in cardiology worldwide and 3rd leading pharmaceutical Group in hypertension worldwide.
Participation reached 38.7% of the trade balance surplus in France
in pharmaceuticals and fine chemicals (brand-name medicines).